Anbioton has been acquired by Elfa Medicamentos
The shareholders of Anbioton have sold the company to Elfa Medicamentos, a Patria Investimentos portfolio company.
Anbioton is focused on the Brazilian pharmaceutical distribution market. The company serves close to 1,400 private hospitals and 200 public entities through partnership agreements with more than 75 pharmaceutical companies.
Elfa Medicamentos was founded in 1989 by Edalmo Leite Fernandes Assis. The company’s operations are focused on the distribution of specialty medicines and generic and branded drugs, hospital supplies, and high value-added solutions for medical plans, clinics, hospitals, government, doctors and patients across the country.
One of Oaklins’ teams in Brazil acted as the exclusive sell-side advisor for Anbioton and its shareholders.


Talk to the deal team
Related deals
Bolster Investment Partners has acquired a majority stake in Eternal Sun
Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreLe Cercle has successfully completed its primary LBO in partnership with FrenchFood Capital and Bpifrance
Le Cercle, a pioneer in reusable meal trays and a leading catering company in the Île-de-France region, is entering a new phase of development with an investment from FrenchFood Capital and the support of Bpifrance. This transaction also marks the appointment of Nathalie Grand-Morin, currently managing director, as the new CEO of the company.
Learn more